Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 7:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 3,667 matching trials from the live ClinicalTrials.gov search.
Conditions
Non-small Cell Lung Cancer
Interventions
AT-101 and docetaxel, placebo and docetaxel
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma
Interventions
VELCADE and rituximab
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
13
States / cities
Los Angeles, California • Fort Myers, Florida • Atlanta, Georgia + 10 more
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, leucovorin calcium, methotrexate, methylprednisolone, allogeneic bone marrow transplantation, in vitro-treated bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
15 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Follicular Lymphoma
Interventions
Abexinostat
Drug
Lead sponsor
Xynomic Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
9
States / cities
Park Ridge, Illinois • Louisville, Kentucky • Lake Success, New York + 5 more
Conditions
Osteosarcoma Recurrent, Osteosarcoma in Children, Relapsed Osteosarcoma, Refractory Osteosarcoma
Interventions
Tegavivint, Gemcitabine
Drug
Lead sponsor
Emory University
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Atlanta, Georgia • Houston, Texas
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Interventions
RAD001, Sorafenib
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa • Rochester, Minnesota
Conditions
Neuroblastoma
Interventions
ZD6474, Retinoic Acid
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Conditions
T-Cell Neoplasm, Lymphoproliferative Disorders
Interventions
Pacritinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Duarte, California • Tampa, Florida • Ann Arbor, Michigan + 3 more
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Anti-CD123 LV redirected T cells (CART123), Ruxolitinib (JAKAVI®)
Biological · Drug
Lead sponsor
Stephan Grupp MD PhD
Other
Eligibility
0 Years to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Electronic Health Record Review
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Interventions
Selinexor 40 mg
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mucosa-Associated Lymphoid Tissue Lymphoma, Refractory Follicular Lymphoma, Refractory Hairy Cell Leukemia, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
Interventions
Lenalidomide, Obinutuzumab, Oral Azacitidine
Drug · Biological
Lead sponsor
Joseph Tuscano
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Sacramento, California
Recruiting No phase listed Observational

Delayed Toxicities Post-CAR-T

NCT07665307
Conditions
Multiple Myeloma
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
San Francisco, California • New York, New York
Conditions
CD22 Positive, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
Interventions
Inotuzumab Ozogamicin
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Small Cell Lung Cancer, Advanced Solid Malignant Tumor
Interventions
Chiauranib
Drug
Lead sponsor
Chipscreen Biosciences, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Encinitas, California • Fullerton, California • Atlanta, Georgia + 8 more
Conditions
Neuroblastoma
Interventions
DFMO, Celecoxib, Cyclophosphamide, Topotecan
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
2 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, IMGN632, Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
13
States / cities
Duarte, California • Orange, California • Tampa, Florida + 10 more
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Loncastuximab Tesirine, Mosunetuzumab, Positron Emission Tomography
Procedure · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Duarte, California
Conditions
Leukemia
Interventions
imatinib mesylate
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
BTX-A51, Azacitidine
Drug
Lead sponsor
Edgewood Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Duarte, California • New York, New York • Houston, Texas
Conditions
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Blastic Phase, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome
Interventions
Sorafenib Tosylate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Tisagenlecleucel, Pembrolizumab
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas
Conditions
Lymphoma, Non-Hodgkin
Interventions
CC-96673
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Minneapolis, Minnesota • Omaha, Nebraska • Houston, Texas + 1 more
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABT-199, Rituximab, Bendamustine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
8
States / cities
La Jolla, California • Los Angeles, California • Atlanta, Georgia + 5 more